{"id":"W4405043193","doi":"10.1182/blood-2024-200336","title":"Belantamab Mafodotin, Bortezomib, and Dexamethasone Vs Daratumumab, Bortezomib, and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Overall Survival Analysis and Updated Efficacy Outcomes of the Phase 3 Dreamm-7 Trial","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"ca_institutions":"GlaxoSmithKline (Canada)","funders":"","keywords":"Daratumumab; Bortezomib; Dexamethasone; Medicine; Multiple myeloma; Internal medicine; Oncology; Refractory (planetary science); Lenalidomide; Biology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003464959,0.0008878883,0.00184514,0.0004196433,0.0002094075,0.001188073,0.0006555982,0.0008689389,0.001649571],"category_scores_gemma":[0.001531971,0.0003102059,0.002772692,0.0004849776,0.0005576759,0.001051629,0.0004990351,0.002493362,0.0003492688],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008746381,"about_ca_system_score_gemma":0.0007722022,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000679828,"about_ca_topic_score_gemma":0.002336416,"domain_scores_codex":[0.9989771,0.0006193299,0.00005782318,0.0001138381,0.0001056527,0.0001262958],"domain_scores_gemma":[0.9989803,0.0002743707,0.0003101653,0.00006392192,0.00005216479,0.0003189875],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8935806,0.004101544,0.009533092,0.0008122331,0.007156085,0.00006256762,0.00009180098,0.003122211,0.00440568,0.0003704653,0.004057676,0.07270602],"study_design_scores_gemma":[0.6888509,0.211874,0.06495657,0.0003454817,0.01356717,0.0003926771,0.0001855974,0.00562163,0.002409574,0.001945568,0.009756495,0.00009433197],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9703532,0.02286832,0.0004547539,0.001441416,0.0004311617,0.0004278581,0.001698345,0.00005698082,0.002268065],"genre_scores_gemma":[0.9865564,0.006140884,0.0006311587,0.001248398,0.0004248565,0.0004794654,0.003121902,0.00002506303,0.001371882],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003464959,"threshold_uncertainty_score":0.01832461,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0225832048316759,"score_gpt":0.3177797423008171,"score_spread":0.2951965374691412,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}